批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期 | 提交号 | 审批结论 | 申请内容分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
2022/09/30 |
SUPPL-57(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2021/05/06 |
SUPPL-55(补充) |
Approval |
REMS |
N/A
|
|
|
2021/03/04 |
SUPPL-52(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2020/05/08 |
SUPPL-49(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2019/09/06 |
SUPPL-45(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2019/06/07 |
SUPPL-44(补充) |
Approval |
REMS |
N/A
|
|
|
2018/12/28 |
SUPPL-42(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2016/12/12 |
SUPPL-35(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2016/12/09 |
SUPPL-33(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2016/05/20 |
SUPPL-32(补充) |
Approval |
REMS |
N/A
|
|
|
2016/05/19 |
SUPPL-31(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
2016/01/19 |
SUPPL-30(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
2015/12/08 |
SUPPL-29(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
2015/01/26 |
SUPPL-28(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
2014/08/29 |
SUPPL-27(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
2014/04/17 |
SUPPL-26(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
2014/02/09 |
SUPPL-24(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
2014/01/07 |
SUPPL-25(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
2013/07/29 |
SUPPL-23(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2013/07/29 |
SUPPL-20(补充) |
Approval |
REMS |
N/A
|
|
|
2013/03/28 |
SUPPL-21(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
2010/10/12 |
SUPPL-15(补充) |
Approval |
Efficacy |
PRIORITY
|
|
|
2010/08/18 |
SUPPL-6(补充) |
Approval |
Manufacturing (CMC) |
N/A
|
|
|
2010/03/22 |
SUPPL-10(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2010/03/22 |
SUPPL-5(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2007/10/26 |
SUPPL-3(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2006/04/13 |
ORIG-1(原始申请) |
Approval |
Type 3 - New Dosage Form |
PRIORITY
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
与本品治疗等效的药品
活性成分:NALTREXONE 剂型/给药途径:FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 规格:380MG/VIAL 治疗等效代码:AP
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
021897 |
001 |
NDA |
VIVITROL |
NALTREXONE |
FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR |
380MG/VIAL |
Prescription |
Yes |
Yes |
AP |
2006/04/13
|
ALKERMES |
213195 |
001 |
ANDA |
NALTREXONE |
NALTREXONE |
FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR |
380MG/VIAL |
Discontinued |
No |
No |
AP |
2023/07/06
|
TEVA PHARMS USA INC |